TrialNeuro-oncology2023

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.

Andrew B Lassman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.